A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

Exclusion Criteria

• •1. Chronic obstructive pulmonary disease or other significant lung disease
• •2. Oral/SCS use (any dose) within 6 weeks before Visit 1
• •3. Chronic use of OCS ≥ 3 weeks use in 3 months prior to Visit 1
• •4. Having received any marketed or investigational biologic within 3 months or 5 half-lives before Visit 1, whichever is longer, or any other prohibited medication
• •5. Current smokers, former smokers with \> 10 pack-years history, or former smokers who stopped smoking \< 6 months before Visit 1
• •6. Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within last 5 years of Visit 1
• •7. Completed treatment for lower respiratory infection or asthma exacerbation within 6 weeks of Visit 1
• •8. Upper respiratory infection involving antibiotic treatment not resolved within 7 days before Visit 1
• •9. Clinically significant laboratory abnormalities
• •10. Historical or current evidence of a clinically significant disease
• •11. Cancer not in complete remission for at least 5 years before Visit 1
• •12. History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting informed consent validity
• •13. Have a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients
• •14. Inability to abstain from protocol-defined prohibited medications during the study
• •15. Having received a live attenuated vaccination within 7 days of Visit 1
• •16. Currently pregnant or breastfeeding
• •17. Participants who experience \> 1 asthma exacerbation during the screening period